One-year costs of second-line therapies for depression

Journal of Clinical Psychiatry

Volumn 61, Issue 4, 2000, Pages 290-298

  Sullivan, Erin M ^a   Griffiths, Robert I ^a,b   Frank, Richard G ^c   Strauss, Michael J ^a   Herbert, Robert J ^a   Clouse, Jon ^d   Goldman, Howard H ^e  

^a UK   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Ingenix Kent McNeill   (United States)

^e Johns Hopkins Univ Sch of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RESOURCE ALLOCATION; SEX DIFFERENCE;

EID: 0034103816     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0409     Document Type: Article

References (29)

1. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-419
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
3. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. Pharmacoeconomics 1995;7:284-291
4. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
5. Johnson RE, McFarland BH, Nichols GA. Changing patterns of anti-depressant use and costs in a health maintenance organization. Pharmaco-economics 1997;22:274-286
6. Derivan A, Entsvah R, Kikta D. Venlafaxine: measuring the onset of anti-depressant action. Psychopharmacol Bull 1995;31:439-447
7. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):5-20
8. Nierenberg A, Feighner J, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
9. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55:3-15
10. Fawcett J. Quality of antidepressant treatment response: partial response in the clinical management of chronic depression. Presented at the 1st International Conference on Mood Disorders; April 2-3, 1993; London, England
11. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 1995;10:21-27
12. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994;55(9, suppl A):42-52
13. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-329
14. Priest RG. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Clin Therapeutics 1996;18:347-358
15. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997;12:286-296
16. LePen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994;31:1-18
17. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16:715-730
18. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research 1995;56:556-567
19. DRGs: Diagnosis Related Groups Definitions Manual Version 12.0. Wallingford, Conn: 3M Health Information Systems; 1994. Document No. 94-06 Rev 00
20. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412
21. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408
22. Aguiar LM, Haskins T, Rudolph RL, et al. Double-blind, placebo-controlled study of once-daily venlafaxine extended release in outpatients with GAD. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Ontario, Canada. Abstract NR643:241
23. Entsuah R, Derivan AT, Haskins T, et al. Double-blind, placebo-controlled study of once daily venlafaxine extended release and buspirone in outpatients with GAD. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Ontario, Canada. Abstract NR644:241
24. Rost K, Smith GR, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994;3:333-337
25. Katon W, Robinson P, Vonkorff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996;53:924-932
26. Katzelnick DJ, Kobak KA, Jefferson JW, et al. Prescribing patterns of anti-depressant medications for depression in a HMO. Formulary 1996;31: 374-388
27. Browne RA, Melfi CA, Croghan TW. et al. Issues to consider when conducting research using physician-reported antidepressant claims. Drug Benefit Trends 1998;10:33-42
28. Beasley CM, Sayler ME, Cunningham GE, et al. Fluoxetine and tricyclic refractory major depressive disorder. J Affect Disorder 1990;20:193-200
29. Joffe RT, Levin AJ, Sokolov STH. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 1996;57(suppl 7):25-31